AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
20/20 Biolabs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.26−0.00 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$14.5177 (−98.24%)since Feb 20, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
20/20 Biolabs, Inc. grew revenue 16.7% to $2.05M over fiscal 2025.
Revenue
$2.05M
+16.7% vs. a year earlier
Operating income
-$3.33M
FY2025
EPS, diluted
-$0.76
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $2.81M
- P/E ratio
- –
- Price to sales
- 1.37
- Price to book
- 1.73
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.05M
- Net income
- -$3.74M
- EPS, diluted
- -$0.76
- Book value per share
- $0.15
- Diluted shares
- 11M
Three years at a glance
Fiscal years 2023 to 2025, USD
Revenue
$2.05M+16.7% YoY
Gross profit
$604.54K+67.8% YoY
Operating income
-$3.33M
Net income
-$3.74M
EPS, diluted
-$0.76
Reported period